Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

Recent Financial News

IR Contacts

MZ Group

Chris Tyson
Managing Director - MZ North America
Direct: 949-491-8235
NDRA@mzgroup.us
www.mzgroup.us

Stock Performance

Today's Open 2.24
Volume 168,396
Day Range 2.10 - 2.34
52 Week Range 1.55 - 5.88
Bid/Ask 2.11 / 2.15
Bid/Ask Size 200 X 500
Previous Close 2.25
Market Cap 11.61 million
Shares Outstanding 5.43 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -2.477200
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Nov 05, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 13, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 15, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Apr 13, 2018 10-K/A Annual report (Amendment) htmlhtml   pdfpdf  
Mar 20, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David R. Wells, Chief Financial Officer

Steve Freeman, Human Resources Leader

Board of Directors

Francois Michelon, Chairman of the Board

Anthony DiGiandomenico, Director

Dr. Sanjiv Sam Gambhir, Director

Michael Harsh, Director

Alexander Tokman, Director